About Us

Mātai is a not-for-profit research centre based in Gisborne-Tairāwhiti, New Zealand.
Mātai is focused on enhancing the capabilities of medical imaging using new and advanced software, post-processing and artificial intelligence. We take a collaborative approach, drawing on a network of leading expertise nationally and internationally.
We lead our research with a view to kaupapa Māori and to support our community on our journey toward a better understanding of a healthy brain, heart, and body.

ABOUT US

Mātai means ‘to investigate or examine’. Our whakatauāki, Te Mata Mātai Hura, means ‘the investigative revealing eye’.

We are a non-profit entity, with a collaborative, multi-disciplinary outlook, drawing on a network of leading expertise nationally and internationally. A strong focus is on using our facilities and expertise to support our local community health needs, that could lead to positive health outcomes.

OUR VISION

To enable strength, health, and innovation for our whānau and our people through world-leading imaging discoveries.

ACKNOWLEDGEMENTS

We would like to thank and acknowledge the New Zealand Government for the Provincial Growth Fund (PGF) contribution.

Our team would also like to extend our sincere appreciation to the Eastland Community Trust (ECT), Activate Tairāwhiti and the University of Auckland for their support.

We received generous support from many volunteers, collaborators, and organisations, including the Centre for Brain Research, Malaghan Institute, Auckland Bioengineering Institute, Centre for Advanced MRI, Hauora Tairāwhiti (TDHB), Ngāti Porou Hauora, Turanga Health, Business Success Partners NZ Ltd., Coates Associates Gisborne, FireUP, Pultron Composites Ltd., Callaghan Innovation, BRNZ, and Manaaki Tairāwhiti.

A special note of thanks goes to Mark Kopua for his gift of our name and whakatauāki.

Structure

Mātai will operate as a non-profit entity, governed by a charitable trust. The entity will include an incubation arm that will serve to commercialize IP and products. Revenues from commercial operations will be reinvested into further research.